Pathology of borderline HER-2/neu breast carcinoma: A biologically distinct phenotype

Breast Cancer Research and Treatment

Volumn 98, Issue 1, 2006, Pages 99-108

  Killeen, Jeffrey L ^a   Ortega Lopez, Anna ^a   Shaha, James ^b   Shaha, Steven H ^b   Fu, Jennifer B ^a,c  

^a KAPIOLANI MEDICAL CENTER FOR WOMEN AND CHILDREN   (United States)

^b STRAUB CLINIC AND HOSPITAL   (United States)

^c UNIVERSITY OF HAWAII   (United States)

Author keywords

FISH; HER 2 neu; Hormone receptors; Image analysis; Tumor biology

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR; PROGESTERONE RECEPTOR; TUMOR MARKER;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER INCIDENCE; CANCER INVASION; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; PHENOTYPE; RECEPTOR, ERBB-2;

EID: 33745911961     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-005-9136-1     Document Type: Article

References (32)

1. Cancer Facts & Figures. American Cancer Society, www.cancer.org, 2005
2. Pauletti G, Dandekar S, Rong HM, Ramos L, Peng H, Seshadri R, Slamon DJ: Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 18: 3651-3664, 2000
3. Yaziji H, Goldstein L, Barry TS, Werling R, Hwang H, Ellis GK, Gralow JR, Livingston RB, Gown AG: HER-2 testing in breast cancer using parallel tissue-based methods. JAMA 291: 1972-1977, 2004
4. Bloom K, Harrington D: Enhanced accuracy and reliability of HER-2/neu immunohistochemical scoring using digital microscopy. Am J Clin Pathol 121: 620-630, 2004
5. Wang S, Saboorian MH, Frenkel EP, Haley BB, Siddiqui MT, Gokaslan S, Wians FH, Hynan L, Ashfaq R: Assessment of HER-2/neu status in breast cancer: automated cellular imaging system (ACIS) - assisted quantitation of immunohistochemical assay achieves high accuracy in comparison with fluorescence in situ hybridization assay as the standard. Am J Clin Pathol 116: 495-503, 2001
6. Arpino G, Weiss H, Lee AV, Schiff R, De Pacido S, Osborne CK, Elledge RM: Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistence. J Natl Cancer Inst 97: 1254-1261, 2005
7. Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19: 403-410, 1991
8. Tubbs RR, Pettay JD, Roche PC, Stoler MH, Jenkin RB, Grogan TM: Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol 19: 2714-2721, 2001
9. Press MF, Slamon DJ, Flom KJ, Park J, Zhou JY, Bernstein L: Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol 20: 3095-3105, 2002
10. Killeen JL, Fu JB: Validation of HER-2/neu testing by image analysis. Breast Cancer Research and Treatment 88, supplement 1, San Antonio Breast Cancer Symposium, 2004, p. S45-S46
11. Perez E: Update of Breast Intergroup Trial N9831. Proc American Society of Clinical Oncology, 2004, p. 19s
12. Hicks DG, Tubbs RR: Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines. Human Pathol 36: 250-261, 2005
13. Zarbo RJ, Hammond EH: Her-2/neu testing of breast cancer patients in clinical practice. Arch Pathol Lab Med 127. Conference Summary, Strategic Science Symposium, 2003, pp. 549-553
14. Lal P, Tan LK, Chen B: Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3655 invasive breast carcinomas. Am J Clin Pathol 123: 541-546, 2005
15. Hammock L, Lewis M, Phillips C, Cohen C: Strong HER-2/neu Protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization. Hum Pathol 34: 1043-1047, 2003
16. Kakar S, Puangsuvan N, Stevens JM, Serenas R, Mangan G, Sahai S, Mihalov ML: HER-2/neu assessment in breast cancer by immunohistochemistry and fluorescence in situ hybridization: comparison of results and correlation with survival. Mol Diagn 5: 199-207, 2000
17. Ariga R, Zarif A, Korasick J, Reddy V, Siziopikou K, Gattuso P: Correlation of Her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma. Breast J 11: 278-280, 2005
18. Stal O, Borg A, Ferno M, Kallstrom AC, Malmstrom P, Nordenskjold B: ErbB2 status and the benefit from two to five years of adjuvant tamoxifen in postmenopausal early stage breast cancer. Ann Oncol 11: 1545-1550, 2000
19. Borg A, Baldetorp B, Ferno M, Killander D, Olsson H, Ryden S, Sigurdsson H: ERBB2 amplification is associated with tamoxifen resistance in steroid receptor positive breast cancer. Cancer Lett 81: 137-144, 1994
20. Houston SJ, Plunkett TA, Barnes DM, Smith P, Rubens RD, Miles DW: Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br J Cancer 79: 1220-1226, 1999
21. Nordenskjold B, Hatschek T, Kallstrom A: Results of prolonged adjuvant tamoxifen therapy in breast cancer correlated to steroid receptor, S-phase and erbB2 levels. Proc Am Soc Clin Oncol 18: 70a, 1999
22. Spyratos F, Bouchet C, Ferrero-Poüs M, Tubiana-Hulin M, Hacene K: Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst 95: 1417, 2003
23. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351: 1451-1467, 1998
24. Coradini D, Oriana S, Biganzoli E, Marubini E, Boracchi P, Bresciani G, Di Fronzo G, Daidone MG: Relationship between steroid receptors (as continuous variables) and response to adjuvant treatments in postmenopausal women with node-positive breast cancer. Int J Biol Markers 14: 60-67, 1999
25. Harvey JM, Clark GM, Osborne CK, Allred DC: Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17: 1474-1481, 1999
26. Elledge RM, Green S, Pugh R, Allred DC, Clark GM, Hill J, Ravdin P, Martino S, Osborne CK: Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immunohistochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group study. Int J Cancer 89: 111-117, 2000
27. Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM: Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 21: 1973-1979, 2003
28. Ravdin PM, Green S, Dorr TM, McGuire WL, Fabian C, Pugh RP, Carter RD, Rivkin SE, Borst JR, Belt RJ: Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J Clin Oncol 10: 1284-1291, 1992
29. Tagliabue E, Menard S, Robertson JF, Harris L: C-erbB-2 expression in primary breast cancer. Int J Biol Markers 14: 16-26, 1999
30. Konecny G, Pauletti G, Pegram M, Untch M, Dandkar S, Aguilar Z, Wilson C, Rong H-M, Bauerfeind I, Felber M, Wang H-J, Beryt M, Seshadri R, Hepp H, Slamon DJ: Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst 95: 142-153, 2003
31. Fuqua SA, Fitzgerald SD, Chamness GC, Tandon AK, McDonnell DP, Nawaz Z, O'Malley BW, McGuire WL: Variant human breast tumor estrogen receptor with constitutive transcriptional activity. Cancer Res 51: 105-109, 1991
32. Wang H, Zeng X, Khan SA: Estrogen receptor variants Erdelta5 and Erdelta7 down-regulate wild-type estrogen activity. Mol Cell Endocrinol 156: 159-168, 1999